Table 2.

Summary of comparative studies examining efficacy of cefiderocol in patients with A. baumannii infections.

Study (Year)	No. of Evaluable	Infection ¶	Antibacterial Regimens No. Pts				Cure and/or Improvement (%) Mortality (%)			Bacteriological Eradication (%)
			Comparator 1		Comparator 2		Comparator 1	Comparator 2	p-Value	Comparator 1	Comparator 2	p-Value
33	47	Pneumonia	CFD	23	MR	24	52	58	NS	39	33	NS
							M:19	M:22	NS
34	54	Pneumonia/B/UTI	CFD	37	BAT	17	43	53	NS	27	29	NS
							M:49	M:18	NR
36	107	B:27 LRTI:14 ALL COVID-19	CFD	42	COL−R	65	40	36	0.45	28	21	0.24
							M:55	M:58	0.70
37	124	B:79 VAP:35	CFD−R	47	COL−R	28	NR	NR
							M:34%	M:55.8	0.018 *	82.6	93.2	0.079
38	111	B:53 P:47	CFD−R	60	COL−R	51	73	67	0.44	43	41	0.82
							M:51	M:37
39	118	B	CFD−R	43	COL−R	75	NR	NR		NR	NR
							M:40	M:59	0.045
40	121	VAP ALL COVID-19	CFD−R	55	NON CFD−R	66	NR	NR		47	69	0.038
							M:44	M:67	0.011
41	90	VAP	CFD+Ncol	40	COL+nCOL	50	75	52	0.02	70	40	0.003
							M:35	M:52	NS
42	73	Bacteremic VAP ALL COVID-19	CFD−R	19	COL−R	54	NR	NR		NR	NR
							M:31.5	M:98.1	<0.001

Abbreviations: No. = number; Pts = patients; M = mortality; ^¶ = numbers in the infection column are absolute numbers of patients with the specific type of infection mentioned; VAP = Ventilator-associated pneumonia; p = pneumonia; LRTI = lower respiratory tract infection; B = bloodstream infection; CFD = cefiderocol; CFD-R = cefiderocol-containing regimen; COL-R = colistin-containing regimens, i.e., combination regimens ± monotherapy; COL = Colistin; nCOL = nebulised colistin; * = regarding mortality of bacteraemia only; MR= meropenem; BAT = best available treatment; NR = not reported; NS = non-significant.